Skip to main content

Immunotherapy in type 1 diabetes

Editor:

Sérgio Vencio: Institute of Pharmaceutical Sciences (ICF), Brazil
Marcello Casaccia Bertoluci: Universidade Federal do Rio Grande do Sul, Brazil

Submission Status: Open   |   Submission Deadline: 31 May 2024


Diabetology & Metabolic Syndrome is calling for submissions to our collection on Immunotherapy in type 1 diabetes. Type 1 diabetes is an autoimmune disease and characterize by the cell death of islet β-cells by patient’s immune system. Although discovery of insulin and its administration remained as only possible therapy, risk of long-term effects on eye and kidney along with chances of mortality remains concerning. Unfortunately, most data regarding immunotherapy are at the experimental level and only pre-clinical trial results are available. More research is needed to conclude its safety and efficacy in larger populations. However, in future, immunotherapy remains as the hope for treating Type 1 diabetes without insulin administration.

Image credit: © Gilnature / Getty Images / iStock

About the collection

Diabetology & Metabolic Syndrome is calling for submissions to our collection on Immunotherapy in type 1 diabetes. Type 1 diabetes is an autoimmune disease and characterize by the cell death of islet β-cells by patient’s immune system. Once these cells are destroyed, no regeneration occurs, leading to high blood glucose level. Although discovery of insulin and its administration remained as only possible therapy, risk of long-term effects on eye and kidney along with chances of mortality remains concerning. One possible cure is the immunotherapy after the early screening and detection of type 1 diabetes before the onset of the disease, when a reasonable amount of the cells is still actively producing insulin. Immunotherapy for type 1 diabetes includes islet cell transplantation and subsequent administration of immune modulating drugs, antigen specific therapies and thus reduction of body’s immune response or enhancing tolerance to β-cell antigens, in most of the cases generating concerning side effects.  Unfortunately, most data regarding immunotherapy are at the experimental level and only pre-clinical trial results are available. More research is needed to conclude its safety and efficacy in larger populations. However, in future, immunotherapy remains as the hope for treating Type 1 diabetes without insulin administration.

This collection thus encourages manuscript (original articles, reviews, clinical interventions, case study) addressing recent advances in the overall theme of immunotherapy in type 1 diabetes and the respective outcomes.

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles, Data Notes, Case Reports, Study Protocols, and Database Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a collection, please select "Immunotherapy in type 1 diabetes" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.